Table of Contents 3
List of Tables 5
List of Figures 5
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Agenus Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Agenus Acquires Antibody Manufacturing Facilities from XOMA 14
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16
Agenus Acquires Antibody Assets of Celexion 17
Venture Financing 18
PhosImmune Raises Funds through Venture Financing 18
Partnerships 19
Agenus Enters into Agreement with National Cancer Institute 19
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21
Licensing Agreements 22
Agenus Enters into Licensing Agreement with IONTAS 22
Agenus Enters into Licensing Agreement with Diatheva 23
Merck Extends Licensing Agreement with Agenus 24
Incyte Amends Licensing Agreement with Agenus 25
Agenus Enters into Licensing Agreement with Ludwig Institute 27
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29
PhosImmune Enters into Licensing Agreement with Pure MHC 30
Equity Offering 31
Agenus to Raise Funds through Public Offering of Shares 31
Agenus Plans to Raise Funds through Public Offering of Shares 32
Celexion Sells its Stock to Agenus for USD4.3 Million 33
Agenus Plans to Raise Funds through Public Offering of Shares 34
Agenus Raises USD80 Million in Public Offering of Shares 35
Agenus Raises USD35 Million in Private Placement of Common Stock 37
Agenus Completes Public Offering Of Shares For US$60 Million 39
Agenus Completes Private Placement Of Shares For US$10 Million 41
Agenus Completes Private Placement Of Shares For US$8 Million 42
Agenus Completes Private Placement Of Shares For US$3 Million 43
Debt Offering 44
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44
Agenus Completes Private Placement Of Notes Due 2015 For US$5 Million 46
Asset Transactions 47
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47
Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48
Acquisition 50
Agenus Acquires PhosImmune 50
Agenus Completes Acquisition Of 4-Antibody For US$50 Million 51
Agenus Inc - Key Competitors 53
Agenus Inc - Key Employees 54
Agenus Inc - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 56
Strategy And Business Planning 56
Oct 23, 2017: Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics 56
Financial Announcements 57
Aug 09, 2018: Agenus reports second quarter 2018 financial results and provides corporate update 57
May 07, 2018: Agenus Annnounces First Quarter 2018 Financial Results 58
Nov 07, 2017: Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update 59
Aug 03, 2017: Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update 60
May 04, 2017: Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update 61
Mar 09, 2017: Agenus Reports Fourth Quarter and Full Year 2016 Results 63
Corporate Communications 65
Oct 23, 2017: Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus 65
Mar 30, 2017: Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies 66
Jan 30, 2017: Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer 67
Product News 68
05/17/2018: Agenus to Present Clinical Data on AGEN2034 at ASCO 2018 68
Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034) 69
Clinical Trials 70
Jun 04, 2018: Agenus Presents Clinical Response of AGEN2034 (anti-PD-1) at ASCO 2018 70
Jun 04, 2018: Agenus Presents Clinical Responses of AGEN1884 at ASCO 2018 71
May 17, 2018: Agenus to Present Clinical Data on AGEN-1884 at ASCO 2018 72
Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the AACR 2018 Annual Meeting 73
Nov 09, 2017: Agenus To Present Data on AGEN2034 (PD-1) at SITC 2017 74
Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017 75
Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 76
May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 77
Apr 05, 2017: Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax 78
Mar 07, 2017: Agenus Abstract Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Agenus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11
Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Agenus Acquires Antibody Manufacturing Facilities from XOMA 14
Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16
Agenus Acquires Antibody Assets of Celexion 17
PhosImmune Raises Funds through Venture Financing 18
Agenus Enters into Agreement with National Cancer Institute 19
4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21
Agenus Enters into Licensing Agreement with IONTAS 22
Agenus Enters into Licensing Agreement with Diatheva 23
Merck Extends Licensing Agreement with Agenus 24
Incyte Amends Licensing Agreement with Agenus 25
Agenus Enters into Licensing Agreement with Ludwig Institute 27
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28
Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29
PhosImmune Enters into Licensing Agreement with Pure MHC 30
Agenus to Raise Funds through Public Offering of Shares 31
Agenus Plans to Raise Funds through Public Offering of Shares 32
Celexion Sells its Stock to Agenus for USD4.3 Million 33
Agenus Plans to Raise Funds through Public Offering of Shares 34
Agenus Raises USD80 Million in Public Offering of Shares 35
Agenus Raises USD35 Million in Private Placement of Common Stock 37
Agenus Completes Public Offering Of Shares For US$60 Million 39
Agenus Completes Private Placement Of Shares For US$10 Million 41
Agenus Completes Private Placement Of Shares For US$8 Million 42
Agenus Completes Private Placement Of Shares For US$3 Million 43
Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44
Agenus Completes Private Placement Of Notes Due 2015 For US$5 Million 46
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47
Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48
Agenus Acquires PhosImmune 50
Agenus Completes Acquisition Of 4-Antibody For US$50 Million 51
Agenus Inc, Key Competitors 53
Agenus Inc, Key Employees 54
Agenus Inc, Subsidiaries 55

List of Figures
Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11